RUBIN EYAL (Sr. VP & CFO) received a stock award from PROTALIX BIOTHERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 8/17/2023ACC: 0001104659-23-093070
Officer· Sr. VP & CFO
Since Sep 2019
+201.90K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
201.90K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+201.90K
Price / share
—
Trade value
—
% of position
54.9%
8/15/2023
368.10K→570K
Total
Net shares
+201.90K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/15/2023 | A · Award | +201.90K | — | — | 54.9% | 368.10K | 570K |
| Total | +201.90K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported